Bellicum Pharmaceuticals — Investor Presentation (June 2019)
30 slides from Bellicum Pharmaceuticals's investor presentation, Jun 3, 2019
Slide 1: Investor Presentation
Investor Presentation Striving to deliver cures through controllable cell therapy June 2019
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our CaspaCIDe® (“iC9”), GoCAR-T ® (incorporating “iMC”) and related technologies; our product candidat
Slide 3: Investment Summary
Investment Summary Rivo-cel GoCAR-T Pipeline Allogeneic polyclonal T-cells for hematologic Controllable CAR-T cells designed to optimize malignancies and inherited blood disorders (+HSCT) efficacy and safety European pediatric opportunity clinically de-risked BPX-601 GoCAR-T promising early clinical
Slide 4: Development Pipeline: Rivo-cel and GoCAR-T
Development Pipeline: Rivo-cel and GoCAR-T Controllable cell therapies that may represent major advances in liquid and solid tumors PRODUCT CANDIDATE DISCOVERY CLINICAL PROOF OF CONCEPT PIVOTAL CLINICAL STATUS Rivo-cel Topline data: Rivo-cel iC9 E.U.: Pediatric Leukemias, Lymphomas, and Inherited bl
Slide 5: Technology Overview
Dp) Bellicum Technology Overview
Slide 6: Most Cell Therapies Only Controlled Before Infusion
Most Cell Therapies Only Controlled Before Infusion Limited ability to expand a narrow therapeutic window On Target / Off Tumor GvHD TOXICITY CRS Neurotoxicity BEFORE INFUSION AFTER INFUSION CONTROLLED UNPREDICTABLE Anergy Collect white Genetic Patient blood cells modification infusion Insufficient
Slide 7: Bellicum Platform Designed to Enable Control After Infusion
Bellicum Platform Designed to Enable Control After Infusion Would provide physicians the ability to expand the therapeutic window in each patient iMC ACTIVATION switch to activate immune cells and modulate the iMC tumor micro- environment Potential for BEFORE INFUSION AFTER INFUSION CONTROLLED CONTR
Slide 8: Chemical Induction of Dimerization Molecular Switch Platform
Chemical Induction of Dimerization (“CID”) Molecular Switch Platform Rimiducid infusion activates signaling pathways to control T-cell function 1 VECTOR APPLICATION SPECIFIC Monomeric = Dimerized = Viral transduction ACCESSORY PROTEINS 1 Inactive Proteins Active Proteins transfers the DNA 3 from a v
Slide 9: GoCAR-T Pipeline
Dp) Bellicum GoCAR-T Pipeline
Slide 10: GoCAR-T: Differentiated Approach to Cell Therapy
GoCAR-T: Differentiated Approach to Cell Therapy Current Challenges in Cell Therapy GoCAR-T Benefits Limited efficacy in solid tumors Potential for enhanced efficacy in solid tumors via ▪ Inadequate cell proliferation and iMC signaling persistence to sustain efficacy ▪ MyD88 and CD40 are superior co
Slide 11: BPX-601 GoCAR-T Targeting PSCA
BPX-601 GoCAR-T Targeting PSCA Product Summary Unmet Need High unmet need in solid tumors expressing ▪ Attractive first-in-class solid tumor CAR-T opportunity Prostate Stem Cell Antigen (PSCA) ▪ First-in-human experience with iMC Annual Annual % Expressing Incidence Deaths (US) PSCA ▪ Initial Phase
Slide 12: BPX-601: Phase Trial Progression
BPX-601: Phase 1 Trial Progression BP-012 trial in relapsed/refractory pancreatic, gastric, and prostate cancers Dose Full Efficacy Optimized Lead-in Escalation Conditioning Regimen Dose escalation designed conservatively to evaluate safety Patient Population 2L to 6L Pancreatic 2L Pancreatic • Part
Slide 13: BPX-601: No Dose Limiting Toxicities Observed
BPX-601: No Dose Limiting Toxicities Observed Data presented at ASCO 2019 ▪ No dose limiting toxicities were observed Cohort 0 Cohort 3 Cohort 4 Cohort 5A Cohort 5B All Patients Patients, n (%) n = 3 n = 3 n = 3 n = 4 n = 5 N = 18 Any AE 3 (100) 3 (100) 3 (100) 4 (100) 5 (100) 18 (100) ▪ Adverse Eve
Slide 14: BPX-601: iMC-Driven T Cell Expansion & Persistence
BPX-601: iMC-Driven T Cell Expansion & Persistence Flu/Cy Lymphodepletion Results in Increased BPX-601 Cell Expansion and Persistence Cy Flu/Cy ▪ Peak expansion 4.9-fold higher in Flu/Cy cohort vs Cy alone cohorts ▪ Persistence improves with: ▪ Administration of rimiducid to activate iMC ▪ Higher ce
Slide 15: BPX-601: Evidence of Anti-Tumor Activity
BPX-601: Evidence of Anti-Tumor Activity ▪ 8 (62%) of 13 evaluable patients treated with BPX- 601 and single-dose rim achieved stable disease; 3 had tumor shrinkage of 10-24% ▪ With 9.1 weeks median follow-up (range: 2.9-30.3), median time to next cancer therapy in patients that received subsequent
Slide 16: BPX-603 Dual Switch GoCAR-T Targeting HER2
BPX-603 Dual Switch GoCAR-T Targeting HER2 Product Summary Unmet Need 1 + ▪ HER2 is a validated tumor antigen and is expressed Indication Incidence HER2 5-year OS (Stage IV)1 on numerous solid tumors with high unmet need Gastric 28,000 10-30%3 <20% ▪ Historical HER2 CAR-T studies have shown modest o
Slide 17: Historical HER2 Studies: Modest Clinical Outcomes
Historical HER2 Studies: Modest Clinical Outcomes Study Properties Morgan, 2010 Ahmed, 2015 Feng, 2017 Ahmed, 2017 Hegde, 2019 Construct 4D5-28-BB-z FRP5-28-z Her2-BB-z FRP5-28-z FRP5-28-z Indication(s) Metastatic colon Sarcomas CCA and PCa GBM Sarcomas Patient number 1 19 11 17 10 HER2 expression ≥
Slide 18: BPX-603 Pre-Clinical Studies Demonstrate Potential Clinical Benefits
BPX-603 Pre-Clinical Studies Demonstrate Potential Clinical Benefits Tumor growth Survival 1 0 9 1 0 0 ) C o n tr o l T c e lls r s l / 1 0 8 B P X -6 0 3 + V e h a 2 v 7 5 i m v c B P X -6 0 3 + R im / 7 r s + 1 0 u / s HER2 A549 p ( t 5 0 n e 6 1 0 e c Lung Carcinoma c n r a e i 2 5 5 P 4 d 1 0 (1
Slide 19: RIVO-CEL
Dp) Bellicum RIVO-CEL
Slide 20: Rivo-cel: Opportunity To Transform Treatment Paradigm
Rivo-cel: Opportunity To Transform Treatment Paradigm Current HSCT Treatment paradigm Potential Future HSCT Treatment Paradigm HLA-Matched Toxicity and likelihood MRD Related Donor (MRD) of match Alternative Alternative Alternative HLA-Matched Unrelated Donor (MUD) Alternative rivo-cel MUD + Other D
Slide 21: BP-004 Study: Basis for European Pediatric Approval
BP-004 Study: Basis for European Pediatric Approval Phase 1/2 study of rivo-cel in pediatric patients following TCR 훼β depleted allo-HSCT High risk pediatric αβ T-cell and B-cell Rimiducid for patients who malignancies and non- depleted haplo-HSCT Rivo-cel develop visceral GvHD or are malignant diso
Slide 22: Rivo-cel Interim Results Trend Towards Meeting Primary Endpoint
Rivo-cel Interim Results Trend Towards Meeting Primary Endpoint Interim six-month event-free survival comparable to MUD HSCT Event Free Survival at 180 days ▪ C-004 is an observational trial of pediatric patients with malignant (67%) or non-malignant (33%) disease who underwent a MUD HSCT ▪ Non-infe
Slide 23: Rivo-cel: High Rates of Disease-Free and Overall Survival
Rivo-cel: High Rates of Disease-Free and Overall Survival Interim survival results With median follow-up of N= 166, Events = 9, Overall Survival 94.4% 20.3 months (0.5 – 47.4 (95% CI 90.8-98%) months): ▪ Relapse-free survival 82.9% in malignant patients ▪ Disease-free survival 95.2% in non- malignan
Slide 24: Rivo-cel: High Rates of GvHD Response to Rimiducid
Rivo-cel: High Rates of GvHD Response to Rimiducid Interim results of response in patients refractory to standard of care treatment Methods & Evaluable Population Efficacy Results Translational Results Patients who developed visceral Best overall response of 70% Reduction in rivo-cel serum levels Gv
Slide 25: THRIVE: Registrational Trial in Adults & Adolescents
THRIVE: Registrational Trial in Adults & Adolescents Phase 2/3 study of rivo-cel in intermediate and high risk AML & MDS in patients 12+ years old Phase II Phase III Arm A Patients ≥ 12 years αβ T cell and CD19+ B-cell-depleted haploidentical Cohort 1 † (n= 10) with intermediate stem cell transplant
Slide 26: Rivo-cel Addresses Key Shortcomings
Rivo-cel Addresses Key Shortcomings Rivo-cel addresses shortcomings of stem cell transplants to treat hematological malignancies and inherited blood disorders Rivo-cel Target Market Matched Related Matched Unrelated Haplo and Rivo-cel Donor (MRD) Donor (MUD) Other +HSCT % of Current Market 25-30% ~5
Slide 27: Rivo-cel: Significant Market Opportunity
Rivo-cel: Significant Market Opportunity Potential List Price Patient Population Market Opportunity Additional Opportunities Haplo/ European Initial market: Other: EU Pediatric* 0.4 Pediatric Cost (in thousands) Effectiveness $0.5-0.7 ▪ Geographic expansion TOTAL: 1.8 Analysis MUD: 1.4 billion ▪ U.S
Slide 28: Rivo-cel: Significant Opportunity for EU Pediatric Launch
Rivo-cel: Significant Opportunity for EU Pediatric Launch Pricing & Manufacturing & Demand Team Reimbursement Supply Chain ▪ Encouraging early ▪ Early payer market ▪ Robust manufacturing ▪ Efficient: KOL feedback research encouraging process developed ~75 transplant centers at target pricing represe
Slide 29: Anticipated 2019 and 2020 Key Program Milestones
Anticipated 2019 and 2020 Key Program Milestones 1H’19 2H’19 2020 Presentations of updated Phase 1 results Presentation of updated Phase 1 results Updated Phase 1 and (Flu/Cy regimen) at ASCO (repeat rimiducid dosing) Phase 2 results BPX-601 Amend BP-012 to allow for repeat dosing of rimiducid to re
Slide 30: Investment Summary
Investment Summary Rivo-cel GoCAR-T Pipeline Allogeneic polyclonal T-cells for hematologic Controllable CAR-T cells designed to optimize malignancies and inherited blood disorders (+HSCT) efficacy and safety European pediatric opportunity clinically de-risked BPX-601 GoCAR-T promising early clinical
Bellicum Pharmaceuticals — Investor Presentation (June 2019) on 6ix